About ViAqua
ViAqua Therapeutics was established in September 2014 to address the growing need for effective, affordable health management of diseases in aquaculture. To date, ViAqua has received investments from The Trendlines Group, Nutreco, VisVires New Protein, and the Technion–Israel Institute of Technology, with support from the Israel Innovation Authority.
Achievements
2021: Proven the stability of the product in industrial feed production process; developed an innovative, cost-effective, scalable production process and successfully reached pilot scale
2019: Preparing for high-volume manufacturing and improved product efficacy
Q3 2018: Signed joint development agreement with Skretting SA (Nutreco’s aquaculture division) for first product, including distribution and marketing by Skretting
Q3 2018: Received investment from Nutreco and VisVires New Protein
Q1 2018: Proof-of-concept for oral delivery of first product
ViAqua’s co-founders have PhDs in molecular biology and marine biology, respectively. The Company’s management bring a broad range of business development, technology development, management, and industrial biotech experience.
Current Partners
Shai Ufaz, Ph.D.
CEO & Co-Founder
Molecular biology
Molecular biologist; experience in biotechnology, genetic engineering, protein expression; project manager, Protalix Biotherapeutics, TransAlgae; PhD, plant genetics
Shai Einbinder, Ph.D.
Co-Founder
Marine biology
Marine biologist; experience in product development, management; VP Development & Projects, TransAlgae; CEO, Aurora-V; PhD, marine biology
Prof. Avi Schroeder
Scientific Advisor
Drug delivery
Extensive development in fields of RNA and protein delivery and nanotechnology; Asst. Prof. of Chemical Engineering, Technion-Israel Institute of Technology; postdoctoral fellow with Prof. Robert Langer, MIT
Dganit Vered
Chairperson
Senior corporate & R&D management
Over 20 years’ experience in senior executive positions in R&D, engineering, and operations at Intel, Perrigo, and Hazera Seeds. Professional experience includes former head of R&D in vegetable seeds, VP R&D in the pharma API industry, and various engineering and operations positions in the top-tier silicon wafer industry.
Ami Schlesinger, PhD, MBA
Executive VP Business Development
Marine biology
Marine zoologist with extensive business experience; previously, researcher at TransAlgae; director of R&D at Nanocyte; and executive chairman of business at Ma'agan Michael. Led several firms in senior executive positions spanning diverse fields, including agriculture, aquaculture, desalination, cleantech, energy, trading, precision technology, and plastics.